Many biotech stocks were the darlings of investors during the pandemic as they helped the world fight against the deadly virus by developing vaccines and therapies. However, all stocks in this space could not capitalize on the positive investor sentiment about the industry. Several industry participants, such as Timber Pharmaceuticals, Inc. (TMBR), have delivered disappointing stock market performance this year.
TMBR is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan dermatologic diseases.
